How adverse drug reactions can play a role in innovative drug research.
We describe how adverse drug reactions (ADRs) can play an important role in pharmaceutical research and drug development. Not only do ADRs represent the risks and drawbacks associated with drugs but they can also be related to other knowledge available in pharmaceutical and medical research. We offer a model that can be used to systematically map the pathways through which ADRs can lead to innovative research. These pathways include chemical, therapeutic or pathophysiological steps that can be taken to arrive at new knowledge based on ADRs. We used the development of angiotensin-converting enzyme inhibitors, especially captopril, as a case study. The similarity between the ADR profiles of captopril and penicillamine was a starting point for further innovation. Historical analysis shows that in several instances research in the field of angiotensin-converting enzyme inhibitors has been triggered by ADRs. The model presented here might be applicable to other areas of innovative drug research.
Rikken
F
F
Groningen Institute for Drug Studies (GIDS), University Center for Pharmacy, The Netherlands.
Vos
R
R
D016907:Adverse Drug Reaction Reporting Systems; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D008954:Models, Biological; D010600:Pharmacology / Q000379:methods; D012106:Research; D013329:Structure-Activity Relationship